The Mayo Clinic Score (also called the Mayo Score or Disease Activity Index for Ulcerative Colitis) is the most widely used validated instrument for assessing the clinical and endoscopic activity of Ulcerative Colitis (UC). It was originally developed at the Mayo Clinic and consists of four subscores, each rated from 0 to 3, giving a total possible score of 0 to 12. The four domains are: (1) Stool Frequency — rated relative to the patient's normal baseline: 0 = normal number of stools; 1 = 1–2 more stools than normal per day; 2 = 3–4 more stools per day; 3 = 5 or more stools more than normal per day. (2) Rectal Bleeding — 0 = none; 1 = streaks of blood in less than half of bowel movements; 2 = obvious blood in most bowel movements; 3 = blood alone passed. (3) Endoscopic Findings — 0 = normal or inactive disease; 1 = mild disease (erythema, decreased vascularity, mild friability); 2 = moderate disease (marked erythema, absence of vascular pattern, friability, erosions); 3 = severe disease (spontaneous bleeding, ulceration). (4) Physician's Global Assessment (PGA) — 0 = normal; 1 = mild; 2 = moderate; 3 = severe. Disease activity is classified as: remission (total score 0–2, no sub-score >1); mild disease (3–5); moderate disease (6–10); severe disease (11–12). The Partial Mayo Score (PMS), which omits the endoscopic subscore, is used for day-to-day clinical monitoring and in clinical trials as an endpoint for patient-reported outcomes. The endoscopic subscore alone (Mayo Endoscopic Score, MES) is increasingly used as the primary endpoint in clinical trials, with mucosal healing defined as MES 0 or 1.
Mayo Score = Stool Frequency (0–3) + Rectal Bleeding (0–3) + Endoscopic Findings (0–3) + Physician Global Assessment (0–3); Total 0–12
- 1Assess stool frequency over the past 3 days relative to the patient's normal baseline: score 0 (normal), 1 (+1–2/day), 2 (+3–4/day), 3 (+≥5/day).
- 2Assess rectal bleeding: score 0 (none), 1 (blood streaks <50% of stools), 2 (obvious blood in most stools), 3 (blood alone passed).
- 3Perform colonoscopy or sigmoidoscopy and score endoscopic appearances: 0 (normal/quiescent), 1 (mild), 2 (moderate), 3 (severe/ulceration).
- 4Assign Physician's Global Assessment: 0 (normal), 1 (mild), 2 (moderate), 3 (severe), integrating history, examination, and clinical context.
- 5Sum all four scores: 0–2 = remission; 3–5 = mild; 6–10 = moderate; 11–12 = severe.
- 6For clinical monitoring between endoscopies, use the Partial Mayo Score (stool frequency + rectal bleeding + PGA): 0–1 = remission; 2–4 = mild; 5–7 = moderate.
- 7Correlate with CRP, faecal calprotectin, and haemoglobin to complete the disease activity assessment.
Many clinical trials define remission as Mayo ≤2 with no sub-score >1
A Mayo Score of 1 indicates clinical remission. Endoscopic healing (MES 0) is a deeper remission target associated with better long-term outcomes.
Biologic therapy is appropriate if inadequate response to 5-ASA and corticosteroids
A Mayo Score of 8 represents moderate-severity UC. Biologic therapy or JAK inhibitors are indicated for moderate-to-severe disease inadequately controlled by conventional treatments.
Failure to improve after 3–5 days IV steroids = medical rescue with infliximab 5mg/kg or surgery
Maximum Mayo Score of 12 indicates fulminant UC requiring emergency hospitalisation. IV corticosteroids are first-line with surgical backup available.
Partial Mayo Score ≤2 generally considered clinical remission; fecal calprotectin <150–250 µg/g supports mucosal healing
The Partial Mayo Score allows monitoring between colonoscopies. A PMS of 2 with low calprotectin is reassuring that disease is well-controlled.
Professionals in finance and lending use Mayo Score Uc as part of their standard analytical workflow to verify calculations, reduce arithmetic errors, and produce consistent results that can be documented, audited, and shared with colleagues, clients, or regulatory bodies for compliance purposes.
University professors and instructors incorporate Mayo Score Uc into course materials, homework assignments, and exam preparation resources, allowing students to check manual calculations, build intuition about input-output relationships, and focus on conceptual understanding rather than arithmetic.
Consultants and advisors use Mayo Score Uc to quickly model different scenarios during client meetings, enabling real-time exploration of what-if questions that would otherwise require returning to the office for detailed spreadsheet-based analysis and reporting.
Individual users rely on Mayo Score Uc for personal planning decisions — comparing options, verifying quotes received from service providers, checking third-party calculations, and building confidence that the numbers behind an important decision have been computed correctly and consistently.
Extreme input values
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in mayo score uc calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Assumption violations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in mayo score uc calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Rounding and precision effects
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in mayo score uc calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
| Total Score | Disease Activity | Management |
|---|---|---|
| 0–2 | Remission | Maintain current therapy; surveillance colonoscopy as indicated |
| 3–5 | Mild | Optimise 5-ASA; add topical therapy; consider oral budesonide |
| 6–10 | Moderate | Systemic corticosteroids; step up to biologic/JAK inhibitor if steroid-dependent |
| 11–12 | Severe | Hospitalise; IV hydrocortisone; rescue infliximab or urgent colectomy |
What is the difference between the Full Mayo Score and the Partial Mayo Score?
The Full Mayo Score includes all four domains (stool frequency, rectal bleeding, endoscopy, PGA) and requires colonoscopy or sigmoidoscopy for the endoscopic subscore. The Partial Mayo Score (PMS) omits the endoscopic component and can be completed at any clinical assessment without invasive testing. The PMS is used for day-to-day monitoring between colonoscopies and in clinical trials as a patient-reported outcome measure. Remission by PMS is defined as a score of ≤2 with no individual component >1.
What is mucosal healing and why is it important?
Mucosal healing (MH) refers to the absence of visible endoscopic inflammation, defined as a Mayo Endoscopic Score (MES) of 0 or 1. Achieving MH is associated with significantly better long-term outcomes including lower rates of colectomy, hospitalisation, colorectal cancer, and disease relapse compared to achieving clinical remission alone. Deep remission — combining clinical remission (PMS ≤2) with mucosal healing (MES 0) — is now a treatment target endorsed by ECCO and NICE guidelines.
When is emergency surgery required for severe UC?
Emergency colectomy is indicated for: bowel perforation, massive haemorrhage, toxic megacolon (colonic dilation >5.5 cm with systemic toxicity), or failure to respond to medical rescue therapy. The Oxford Criteria (Travis criteria) are used on day 3 of IV corticosteroid therapy: if CRP >45 mg/L AND stool frequency >3/day OR stool frequency ≥8/day, the risk of colectomy in that admission is 85%. These patients should be discussed with the colorectal surgical team early.
What biologics are approved for moderate-to-severe UC?
Biologics and targeted synthetic agents for UC include: anti-TNF agents (infliximab, adalimumab, golimumab), anti-integrin (vedolizumab — gut-selective with favourable safety), anti-IL-12/23 (ustekinumab), and JAK inhibitors (tofacitinib, upadacitinib, filgotinib). Selection depends on prior exposure, primary/secondary non-response, comorbidities (vedolizumab and ustekinumab preferred in patients with cancer history), and extraintestinal manifestations (anti-TNF preferred for joint and skin manifestations).
What is faecal calprotectin and how is it used in UC monitoring?
Faecal calprotectin (FC) is a neutrophil-derived protein released when intestinal inflammation causes neutrophil migration. It is measured in a stool sample and correlates closely with endoscopic inflammation. FC <150 µg/g suggests endoscopic remission (mucosal healing) with high negative predictive value. FC >250–300 µg/g suggests active inflammation and often triggers early endoscopic reassessment. FC is used to monitor for relapse between colonoscopies, reducing unnecessary invasive investigations.
How is the Mayo Score used in clinical trials?
The Mayo Score is the primary or key secondary endpoint in most UC phase 3 clinical trials. Induction trials (12–16 weeks) typically define clinical response as a ≥3 point or ≥30% reduction in Mayo Score from baseline with ≥1 point decrease in rectal bleeding. Clinical remission is defined as Mayo ≤2 with no sub-score >1. Maintenance trials (52 weeks) use the same definitions. The Mayo Endoscopic Score alone (MES 0 or 1) is increasingly the co-primary endpoint.
What scoring system is used for Crohn's disease?
Crohn's disease activity is assessed using the Harvey-Bradshaw Index (HBI), Crohn's Disease Activity Index (CDAI), and Simple Endoscopic Score for Crohn's Disease (SES-CD). The CDAI is the traditional research gold standard but requires a 7-day diary, making it impractical in routine care. The HBI is simpler and widely used in clinical practice. The Simple Endoscopic Score (SES-CD) assesses endoscopic severity at colonoscopy. There is no single dominant scoring system for Crohn's equivalent to the Mayo Score for UC.
Is colonoscopy surveillance required for patients with long-standing UC?
Yes — patients with extensive colitis (pancolitis or left-sided colitis extending beyond the splenic flexure) or any UC with primary sclerosing cholangitis (PSC) are at increased risk of colorectal cancer (CRC) and require surveillance colonoscopy. NICE and BSG recommend surveillance at 5-year intervals for low-risk (extensive colitis, no other risk factors), 3-year intervals for intermediate risk, and annual colonoscopy for high-risk patients (PSC, previous dysplasia, severe/active endoscopic inflammation).
Pro Tip
Use faecal calprotectin between colonoscopies to monitor for subclinical flare. A rising calprotectin trend (even before symptoms return) is an early warning sign of relapse, allowing pre-emptive optimisation of therapy before full clinical flare occurs. A threshold of 250 µg/g is commonly used to trigger earlier endoscopic reassessment.
Did you know?
Ulcerative colitis was first described as a distinct condition by Sir Samuel Wilks at Guy's Hospital, London, in 1859. He called it 'idiopathic colitis' to distinguish it from infectious dysentery, noting the characteristic bloody diarrhoea and colonic ulceration. The term 'ulcerative colitis' was established by the early 20th century. It wasn't until the 1940s that cortisone treatment (prednisolone) became the first effective medical therapy, following William Heneage Ogilvie's observation that pregnancy (with its natural corticosteroid surge) often induced remission.